Compare Moody's Corporation (MCO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Stryker Corporation — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Stryker Corporation for 21 Days on average.
| MCO | SYK | |
|---|---|---|
Market Cap | $79.44B | $106.24B |
Volume | 526,684 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $539.61 | $388.35 |
52-Week Low | $412.23 | $269.75 |
Typical Hold Time | 132 Days | 21 Days |
Enterprise Value | $85.46B | $117.70B |
Dividend Yield | 0.9% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals. Revenue grew to $7.72B in 2025, with net income margin expanding to 34.25%. Recent news highlights Moody's top RiskTech100 ranking and expansion into Asia-Pacific via a PhilRatings stake. The stock faces resistance near $461, with support at $454.
Outlook remains positive given consistent earnings beats, high profitability, and a $536.40 analyst price target implying 17% upside. Risks include high valuation multiples and macroeconomic sensitivity. Institutional sentiment is bullish with 56% buy ratings, though technical indicators suggest near-term caution.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
